Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-34867
Temme, A; Geiger, K D; Wiedemuth, R; Conseur, K; Pietsch, T; Felsberg, J; Reifenberger, G; Tatsuka, M; Hagel, C; Westphal, M; Berger, H; Simon, M; Weller, M; Schackert, G (2010). Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutation. Journal of Neuropathology and Experimental Neurology, 69(6):632-642.
View at publisher
Giant cell glioblastoma (gcGB), a subtype of GB, is characterized by the presence of numerous multinucleated giant cells. The prognosis for gcGB is poor, but it may have a better clinical outcome compared with classic GB. The molecular alterations that lead to the multinucleated cell phenotype of gcGB have not been elucidated. Giant cell GB has a higher frequency of the tumor suppressor protein p53 mutations than GB, however, and a role for the mitotic Aurora B kinase has been suggested. We analyzed Aurora B expression in gcGB (n = 28) and GB (n = 54) patient tumor samples by immunohistochemistry; 17 gcGB and 22 GB samples were analyzed at the DNA and mRNA levels. No mutations in the Aurora B gene (AURKB) were found, but its mRNA and protein levels were significantly higher in gcGB than in GB. Fifty-nine percent of gcGB samples but only 18% of the GB samples showed p53 mutations. Ectopic overexpression of Aurora B induced a significant increase inthe proportion of multinucleated cells in p53 mutant U373-MG, but not in p53 wild-type U87-MG, glioma cells. RNAi of p53 in U87-MG cells led to an increase in the fraction of multinucleated cells that was further augmented by ectopic overexpression of Aurora B. These results suggest that loss of p53 function and dysregulated Aurora B protein levels might represent factors that drive the development of multinucleated cells in gcGB.
21 downloads since deposited on 15 Jul 2010
7 downloads since 12 months
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology|
|DDC:||610 Medicine & health|
|Deposited On:||15 Jul 2010 15:18|
|Last Modified:||27 Nov 2013 17:59|
|Publisher:||Lippincott Wiliams & Wilkins|
|Additional Information:||This is a non-final version of an article published in final form in Journal of Neuropathology and Experimental Neurology 2010, 69(6):632-642.|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page